RxDoctor Payments Data

Sarah Miller

Gerontology · Bismarck, NDNPI 1003388638

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $191 and has fallen 64.2% since, to $68 in 2025.

$425in general payments, 2019–2025

Across 21 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lexicon Pharmaceuticals, Inc.$81
  • Lundbeck LLC$77
  • Neurocrine Biosciences, Inc.$69
  • Johnson & Johnson$57
  • Acadia Pharmaceuticals Inc$52
  • AbbVie$33
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$425100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gerontology providers in North Dakotato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$81,342
Medicare patients
176
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$49,901
JardianceEmpagliflozin106$24,742
TrulicityDulaglutide21$22,521
XareltoRivaroxaban98$18,427
Modafinil22$14,049
LinzessLinaclotide24$13,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,304
Acetylcysteine51$11,209
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc107$10,853
Mesalamine23$9,265
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$8,731
EntrestoSacubitril/Valsartan23$7,930
Potassium Chloride191$7,792
Tresiba Flextouch U-100Insulin Degludec15$7,768
FarxigaDapagliflozin Propanediol25$7,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$18$24,742106 claims
Lilly USA, LLCTrulicity$21$22,52121 claims
Johnson & JohnsonXarelto$57$18,42798 claims
AbbVieLinzess$33$13,74624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.

Other gerontology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →